Company intelligence / Profile preview

Tarsius Pharma

Zichron Yaacov, Israel

Ownership: Private
Development stage: Other

Overview

TRS01 demonstrated statistically significant improvement in signs and symptoms of uveitis in Phase 1/2 trial (GADOT 20/20), including decrease in anterior chamber cells and pain resolution, with efficacy similar to corticosteroids but without associated side effects. FDA agreement received for Phase 3 trial design under Special Protocol Assessment.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Tarsius Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tarsius Pharma.

Explore the full profile